Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …

abstract Despite significant research efforts, only a few treatment approaches have been
developed for hepatocellular carcinoma (HCC). In recent years, immune checkpoint …

Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical
dependencies,; broad-spectrum kinase inhibitors such as sorafenib provide only a modest …

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death.
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …

While immunotherapy holds great promise for combating cancer, the limited efficacy due to
an immunosuppressive tumor microenvironment and systemic toxicity hinder the broader …

N-linked glycosylation is one of the most abundant posttranslational modifications of
membrane-bound proteins in eukaryotes and affects a number of biological activities …

Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS)
and progression-free survival (PFS) versus sorafenib in patients with unresectable …

Thermal ablative therapies are standard treatments for localized hepatocellular carcinoma
(HCC). In addition to local tumor destruction, ablation leads to abscopal effects in distant …

Purpose The development of treatment-related adverse events (trAE) correlates favorably
with clinical outcomes in multiple studies of patients receiving immune checkpoint inhibitors …

Immunotherapy, which stimulates the body's immune system, has received a considerable
amount of press in recent years because of its powerful benefits. Cancer immunotherapy …